Many people do not get to live their childhood dreams. However, that has not been the case for Dr. Clay Siegall. He is the Founder and the Chief Executive Officer of Seattle Genetics, a biotech company that specializes in the development of targeted cancer therapy drugs. He has seen his corporation develop proprietary drugs like the ADC that have been of great help in the fight against cancer. Their sale has also generated substantial revenues for the institution.
Clay Siegall pursued a Bachelor of Science in Zoology at the University of Maryland. He also holds a Ph.D. in Genetics from the University of George Washington. His career choice was prompted by the fact that healthcare always fascinated him especially the application of new technologies in the treatment of various health conditions. The development of treatment options captivated him, and he wanted to personally experience the feeling of triumph over ailments that have been nerve-wrecking to the society.
Clay Siegall’s had a soft spot for Medicine since his childhood. With the modern development of technology, the idea of practicing Medicine with the help of these new ways enchanted him, and he was ready to dedicate his life to attain it. He wanted to experience its’ might first hand as they fought diseases off people. His interest became more evident than ever while pursuing his college education. During the time, his father fell sick and was diagnosed with the chronic cancer ailment. The available treatment at the time was brutal such that he suffered not so much from the ailment but the hostile effects of the chemotherapy treatment. In an effort to seek better treatments, his desire came into reality, and he joined in the quest to find better therapies for people living with cancer.
Dr. Clay Siegall without a doubt has spanned a successful career with Seattle Genetics. Moreover, he has also served in various reputable institutions. For instance, he has worked at Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and also at the National Institute of Health. Besides, he is presently on the Board of Directors governing Alder BioPharmaceuticals, and he has authored more than 70 publications.